{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:35:26Z","timestamp":1788273326159,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["medical-hypotheses.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.mehy.2013.10.021","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T06:32:01Z","timestamp":1383114721000},"page":"1137-1140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prophylactic broad spectrum antibiotics as a new anti-myeloma therapy"],"prefix":"10.1016","volume":"81","author":[{"given":"Toni","family":"Valkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antica Duletic","family":"Nacinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duska","family":"Petranovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2013.10.021_b0005","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2141.1998.00525.x","article-title":"B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors","volume":"100","author":"Rawstron","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.mehy.2013.10.021_b0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.1983.tb02021.x","article-title":"Abnormal monoclonal antibody-defined helper\/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage","volume":"53","author":"Mills","year":"1983","journal-title":"Br J Haematol"},{"key":"10.1016\/j.mehy.2013.10.021_b0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.leukres.2004.06.003","article-title":"High Th1\/Th2 ratio in patients with multiple myeloma","volume":"29","author":"Ogawara","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.mehy.2013.10.021_b0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2249.2006.03037.x","article-title":"Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma","volume":"144","author":"Brimnes","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.mehy.2013.10.021_b0025","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/ijc.22579","article-title":"Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumour cells","volume":"120","author":"Jarahian","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.mehy.2013.10.021_b0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ajh.2830110402","article-title":"Alternative pathway of complement in multiple myeloma","volume":"11","author":"Kraut","year":"1981","journal-title":"Am J Hematol"},{"key":"10.1016\/j.mehy.2013.10.021_b0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bmt.1700621","article-title":"Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation","volume":"19","author":"Kolbe","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.mehy.2013.10.021_b0040","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.hoc.2007.08.006","article-title":"Complications of multiple myeloma","volume":"21","author":"Blade","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.mehy.2013.10.021_b0045","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0002-9343(81)90303-X","article-title":"Influence of treatment and response status on infection risk in multiple myeloma","volume":"71","author":"Perri","year":"1981","journal-title":"Am J Med"},{"key":"10.1016\/j.mehy.2013.10.021_b0050","first-page":"7","article-title":"For the nordic myeloma study group. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic myeloma study group","volume":"95","author":"Lenhoff","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2013.10.021_b0055","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1053\/j.seminhematol.2009.01.005","article-title":"Management of complications in multiple myeloma","volume":"46","author":"Terpos","year":"2009","journal-title":"Semin Hematol"},{"key":"10.1016\/j.mehy.2013.10.021_b0060","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jcp.48.3.260","article-title":"Immunological factors and risk of infection in plateau phase myeloma","volume":"48","author":"Hargreaves","year":"1995","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.mehy.2013.10.021_b0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/10428199809050943","article-title":"Incidence of sepsis after peripheral blood progenitor cells transplantation: analysis of 86 consecutive hemato-oncological patients","volume":"30","author":"Salutari","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.mehy.2013.10.021_b0070","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.beha.2007.10.001","article-title":"Supportive care in multiple myeloma","volume":"20","author":"Ludwig","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.mehy.2013.10.021_b0075","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V73.2.517.517","article-title":"Paracrine rather then autocrine regulation of myeloma-cell growth and differentiation by interleukine-6","volume":"73","author":"Klein","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2013.10.021_b0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/332083a0","article-title":"Autocrine generation and essential requirement of BSF-2\/IL-6 for human multiple myeloma","volume":"332","author":"Kawano","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2013.10.021_b0085","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863","article-title":"Interleukin-6 in human multiple myeloma","volume":"85","author":"Klein","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2013.10.021_b0090","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like receptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.mehy.2013.10.021_b0095","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.leu.2404226","article-title":"Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Tool-like receptors","volume":"20","author":"Jego","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.mehy.2013.10.021_b0100","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.leu.2404225","article-title":"Toll-like receptors mediate proliferation and survival of multiple myeloma cells","volume":"20","author":"Bohnhorst","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.mehy.2013.10.021_b0105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4161\/cbt.11.1.13878","article-title":"Triggering of toll-like recptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack","volume":"11","author":"Bao","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.mehy.2013.10.021_b0110","first-page":"1697","article-title":"Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia","volume":"91","author":"Landgren","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.mehy.2013.10.021_b0115","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","article-title":"Risk of multiple myeloma and monoclonal gammopathy of undeterminated significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders","volume":"111","author":"Brown","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2013.10.021_b0120","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1182\/blood-2011-04-347559","article-title":"Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study","volume":"118","author":"Lindqvist","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2013.10.021_b0125","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2141.1996.5191061.x","article-title":"Presenting features and prognosis in 72 patients with MM who were younger than 40","volume":"93","author":"Blade","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.mehy.2013.10.021_b0130","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1080\/1042819021000006303","article-title":"BLT-D (clarithromycin, low-dose thalidomide, and dexamthason) for the treatment of myeloma and Waldenstrom\u2019s macroglobulinemia","volume":"43","author":"Coleman","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.mehy.2013.10.021_b0135","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2007-05-090258","article-title":"BIRD (Biaxin[R]\/clarithromycin\/Revlimid[R]lenalidomid\/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma","volume":"111","author":"Niesvizky","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2013.10.021_b0140","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1081-1206(10)62264-8","article-title":"Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study","volume":"87","author":"Spahn","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.mehy.2013.10.021_b0145","first-page":"3723","article-title":"Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB\/c mice","volume":"24","author":"Chara","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.mehy.2013.10.021_b0150","first-page":"815","article-title":"Clarithromycin attenuates autophagy in myeloma cells","volume":"37","author":"Nakamura","year":"2010","journal-title":"Int J Oncol"},{"key":"10.1016\/j.mehy.2013.10.021_b0155","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1902\/jop.2008.080051","article-title":"Doxocycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models","volume":"79","author":"Cazalis","year":"2008","journal-title":"J Periodontol"},{"key":"10.1016\/j.mehy.2013.10.021_b0160","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1749-6632.1994.tb24734.x","article-title":"Treatment of destructive arthritic disorders with MMP inhibitors. Potential role of tetracyclines","volume":"732","author":"Greenwald","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.mehy.2013.10.021_b0165","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bcp.2009.07.028","article-title":"Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells","volume":"79","author":"Garcia-Martinez","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.mehy.2013.10.021_b0170","first-page":"224","article-title":"Doxycycline inhibits proinflammatory cytokines but not acute cerebral cytogenesis after hypoxia\u2013ichemia in neonatal rats","volume":"21","author":"Jantzie","year":"2010","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.mehy.2013.10.021_b0175","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1128\/AAC.42.7.1702","article-title":"16S rRNA mutation associated with tetracycline resistance in a Gram-positive bacterium","volume":"42","author":"Ross","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mehy.2013.10.021_b0180","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1863-2378.2011.01451.x","article-title":"Emerging antimicrobial resistance in commensal Escherichia coli with public health relevance","volume":"59","author":"Kaesbohrer","year":"2012","journal-title":"Zoonoses Public Health"},{"key":"10.1016\/j.mehy.2013.10.021_b0185","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jmii.2013.02.001","article-title":"Comparison of methicillin-resistant Staphylococcus aureus strains isolated in, 2003 and 2008 with an emergence of multidrug resistant ST22: SCCmec IV clone in a territory hospital Malesia","volume":"46","author":"Lim","year":"2013","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.mehy.2013.10.021_b0190","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1473-3099(06)70599-0","article-title":"The worldwide emergence of plasmid-mediated quinolone resistance","volume":"6","author":"Robicek","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.mehy.2013.10.021_b0195","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for prevention of early infection in multiple myeloma","volume":"100","author":"Oken","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.mehy.2013.10.021_b0200","doi-asserted-by":"crossref","unstructured":"Vesole DH, Oken MM, Heckler C, et al. Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study. Leukemia 2012; doi: 10.1038\/leu.2012.124.","DOI":"10.1038\/leu.2012.124"},{"key":"10.1016\/j.mehy.2013.10.021_b0205","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/428732","article-title":"Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and haematological malignancies","volume":"40","author":"Reuter","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mehy.2013.10.021_b0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2141.2001.02487.x","article-title":"Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma","volume":"112","author":"Fassas","year":"2001","journal-title":"Br J Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2013.10.021_b0215","first-page":"353a","article-title":"Autopsy review in multiple myeloma reveals aspergillosis as a significant cause of death after high dose therapy especially with allo-transplants (abstract 1573)","volume":"90","author":"Koneru","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2013.10.021_b0220","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoetic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mehy.2013.10.021_b0225","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987713005070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987713005070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T02:17:24Z","timestamp":1596766644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987713005070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0306987713005070"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2013.10.021","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic broad spectrum antibiotics as a new anti-myeloma therapy","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2013.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}